Table 6

Impact of the treatment phase on the annual ambulatory healthcare expenditures attributable to diabetes for patients with T2DM with normal renal function (€) (Adjusted model on differences in expenditures between T2-DM patients and matched individuals without diabetes)
Treatment phases (ref = monotherapy) Pharmacy Consultations Medical devices Nursing cares Others Total ambulatory costs
Double therapy 238*** 9*** 26*** 9 −31 224***
(213;262) (6;12) (15;38) (-5;23) (-71;9) (169;280)
Triple therapy 556*** 16*** 35** −30* −131*** 411***
(509;603) (11;21) (13;57) (-56;-4) (-208;-55) (306;517)
Insulin therapy 1,224*** 78*** 863*** 1,236*** 1,268*** 3,807***
(1,190;1,259) (74;82) (847;880) (1,217;1,256) (1,212;1,325) (3,730;3,885)

* 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001.

Guelfucci et al.

Guelfucci et al. BMC Endocrine Disorders 2013 13:15   doi:10.1186/1472-6823-13-15

Open Data